The US PASTEUR Act falls short in addressing antimicrobial resistance

The ongoing PPR negotiations at WHO offer an opportunity to resolve the decades-long tension between IP and access

Principles and actions for equitable access to medical products

MSF’s recommendations on the WHO Pandemic Prevention, Preparedness and Response Accord zero draft

The UK has tabled harmful provisions that threaten to tighten the screws on producing, supplying and exporting affordable generic medicines from India

The patent opposition mechanism is a critical public health safeguard under the Indian Patents Act

Voluntary licenses represent one approach to managing intellectual property (IP) for medicines and granting permissions to alternate suppliers to enter the market with more affordable generic products.

Regarding the European Commission’s proposed roadmap “Pharmaceutical Strategy: Timely patient access to affordable medicines”, this briefing document shares some considerations and recommendations based on MSF’s 20 years of experience ...

In July 2020, the European Commission opened a public consultation for feedback to its roadmap for an intellectual property (IP) action plan. In its feedback, Médecins Sans Frontières emphasized that stringent IP enforcement measures ...

MSF is responding to the global COVID-19 pandemic, providing treatment and care for people with COVID-19, protecting people living in vulnerable conditions, and ensuring uninterrupted essential health services. Having universal access ...

Médecins Sans Frontières Access Campaign’s (MSF AC) response to the Public discussion - Draft terms of reference of the Independent Panel on Evidence for Action Against Antimicrobial Resistance

From 2017, MSF has conducted a series of analyses aiming to have a better understanding of the causes of market monopoly in the field of diagnostics for infectious diseases especially concerning TB, HIV/AIDS and HCV. These documents ...

How pharma games the patent system to maximise profits